AstraZeneca amends collaboration with Ironwood for Linzess in China
18 September 2019 07:00 BST AstraZeneca amends collaboration with Ironwood for Linzess in China New agreement gives AstraZeneca full responsibility for developing, manufacturing and commercialising Linzess in China AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess* (linaclotide), a first-in-class new treatment for